LUZHU BIOTECH-B (02480) announced that the Phase I clinical trial of LZ901 conducted in the United States was successfully completed in September 2025. According to the clinical trial results, both the high-dose and low-dose groups of the LZ901 vaccine demonstrated good safety and immunogenicity compared to the placebo group, laying the foundation for subsequent clinical research.

Based on the Phase I clinical trial results of LZ901 conducted in the United States, both the high-dose and low-dose groups of the LZ901 vaccine showed good safety and immunogenicity compared to the placebo group. The primary objective of this clinical trial was to verify the safety of the vaccine. Only the low-dose group of the LZ901 vaccine experienced mild vaccine-related adverse reactions (4.35%), while neither the high-dose group nor the placebo group experienced vaccine-related adverse reactions.

LZ901 is the group's independently developed investigational recombinant shingles vaccine and represents the group's core product. It is designed to prevent shingles and related complications caused by shingles in adults aged 40 and above, including postherpetic neuralgia.

The Phase III clinical trial of LZ901 in the People's Republic of China has achieved the preset clinical targets and obtained clinical results that meet expectations. As of the date of this announcement, the biologics license application for LZ901 has been accepted by the National Medical Products Administration of China and is currently under evaluation.